Your browser doesn't support javascript.
loading
Resolution of persistent SARS-CoV-2 infection with prolonged intravenous remdesivir and vaccination in a patient post CAR-T.
Ambati, Sai; Ali, Bazga; Seddon, Owen; Godkin, Andrew; Scurr, Martin; Moore, Catherine; Rowntree, Clare; Underwood, Jonathan.
Afiliação
  • Ambati S; Department of Internal Medicine, Cardiff and Vale University Health Board, University Hospital of Wales, Cardiff, Wales, UK. Sai.ambati@wales.nhs.uk.
  • Ali B; Department of Infectious Disease, Cardiff and Vale University Health Board, Cardiff, Wales, UK.
  • Seddon O; Department of Infectious Disease, Cardiff and Vale University Health Board, Cardiff, Wales, UK.
  • Godkin A; Department of Gastroenterology and Hepatology, Division of Infection and Immunity, School of Medicine, Cardiff and Vale University Health Board, Cardiff University, Cardiff, Wales, UK.
  • Scurr M; Division of Infection and Immunity, School of Medicine, Cardiff University, ImmunoServ Ltd, Cardiff, Wales, UK.
  • Moore C; Department of Virology, Cardiff and Vale University, Cardiff, Wales, UK.
  • Rowntree C; Department of Haematology, Cardiff and Vale University Health Board, Cardiff, Wales, UK.
  • Underwood J; Department of Infectious Disease, Division of Infection and Immunity, School of Medicine, Cardiff and Vale University Health Board, Cardiff University, Cardiff, Wales, UK.
Int J Hematol ; 117(5): 765-768, 2023 May.
Article em En | MEDLINE | ID: mdl-36757522
SARS-CoV-2 virus is a single-stranded enveloped RNA virus, which causes coronavirus disease. Most of the immunocompetent patients with SARS-CoV-2 infection do have mild to moderate respiratory illness; however, in immunocompromised patients, the course of infection is unpredictable with high rates of infectivity and mortality. So, it is important to identify the immunocompromised patients early and establish the course of treatment accordingly. Here, we describe a 25-year-old male with background of B cell ALL, post-BMT and CAR-T therapy who received treatment with remdesivir and vaccination and was followed up for six months from the onset of symptoms to post vaccination, which showed resolution of symptoms and improvement of immunological markers. Here, we review the literature concerning the course and treatment of SARS-CoV-2 infection aimed at achieving cure in this patient.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores de Antígenos Quiméricos / COVID-19 Tipo de estudo: Prognostic_studies Limite: Adult / Humans / Male Idioma: En Revista: Int J Hematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores de Antígenos Quiméricos / COVID-19 Tipo de estudo: Prognostic_studies Limite: Adult / Humans / Male Idioma: En Revista: Int J Hematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2023 Tipo de documento: Article